It is pretty much time their new CEO stop being interviewed and stop licking Trump . the stock is going nowhere, every month a new flop. The previous guy was the reseach guy....supposely prepared the company with new compounds.... al ready 2 dead,. The new one is supposed to be the specialist in strategy, marketing and sales. What a start !!!
Lilly- Bristol book it
Charles A. Henriques ( Global Popularity Growing, A Bright Star In Pharma ) Linkedin.com NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
San Francisco Bay Area: Linkedin 1799 Linkedin.com Connections
Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
Eli Lilly _amp_ Co_ NYSE $LLY Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stocks
Did anyone else see $LLY report from http://thesubwaytrader.com/?s=LLY ? It had some interesting information. There are three things i have always loved and never understood-art Making money day trading.
The Subway Trader: Trading Stocks and Making Money
Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
WORLDS LARGEST Non Nuclear Bomb GBU-43 B Massive Ordnance Air Blast
Mother of all bombs GBU-43 B Massive Ordnance Air Blast. U.S. on 04.11.2017 dropped the most powerful conventional bomb in its arsenal on Nangarhar, Afghanis...
Does the FDA think the EMA don't have a clue what they are doing? since the EMA cleared Baricitinib for both doses and cleared it on safety concerns we must assume that the FDA feels the EMA as no credibility...
MSNBC anchors realize that they are corrupt propagandists who overestimated Hillary's chances against Trump.
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%+ POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
LLY should buy Fitbit.
✔️🚩Fake News never covered this story. Oh it was a democrat that is why. Former vice President :JOE BIDEN'S SON IS A DRUG ADDICT AND HAVING AN AFFAIR WITH HIS DECEASED BROTHERS WIFE AND NOW TIM KAINE'S SON DOES THIS ? Democrats Santa Monia's hypocrites.
Jensen Lab, Seattle Children's Research Institute | Seattle Children’s Hospital
At Seattle Children’s, the Jensen Lab is pursuing a cutting-edge treatment that reprograms a child’s defense system to attack and kill cancer cells, without chemotherapy or radiation—or their debilitating side effects.
✔️Lilly - fellow shareholders should President Trump have US Justice Department arrest billionaire convicted felon George Soros for inciting riots and paying for thug who riot in major cities across the US. The paid Soros thugs did $100,000 plus in damages at Berkley College two weeks ago. The lawlessness angry liberals need to stop and stop now. Soon they will get their heads cracked open if they keep it up and start filling up our jails. http://www.independentsentinel.com/soros-behind-56-groups-running-womens-march that left trash everywhere and trashy nasty signs
George Soros Behind 56 Groups Running Bizarre Women's March
The women's march is built on lies and a good deal of the funding comes from George Soros and other leftist groups. It took a liberal feminist...
Interesting colon cancer info out today from their partner HCM
Lilly cannot succeed with continued failures in discovery chemistry. How much was wasted on solanezumab, others? Those in the ranks did not make the poor decisions that led to an absurd amount of money wasted on solanezumab. How about laying off those that "failed" to manage the portfolio? They need a management overhaul! To many fat cats!
Secret Service Agent Tells All - Hillary Clinton is CRAZY - Gary Byrne - Full Interview
Former Secret Service officer Gary Byrne, author of the new book Crisis of Character, which examines Hillary Clinton's conduct under his watch, appeared on M...
LLY has just seen the last of the selling. Looks like a potential push higher with a performance %(week) of 3.33%. Ive been struggling with this stock lately. Some of my other trades have been from aw-esomeSTOCKS which are working out pretty well.